Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood biomarkers may predict cancer treatment side effects

NCT ID NCT07803289

Knowledge-focused Sponsor: University Hospitals Coventry and Warwickshire NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This pilot study investigates whether certain molecules in the blood, called miRNAs and proteins, change during cancer treatment and whether these changes can signal early signs of heart or lung damage. Researchers will compare blood samples from patients receiving radiation or chemotherapy for thoracic cancers with those receiving immunotherapy-based combinations. The goal is to identify patterns that could help predict which patients are at higher risk for treatment-related toxicity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to blood tests that help doctors predict and prevent heart or lung damage from cancer treatments.
What could go wrong
This is a small pilot study, so the findings may not apply to all patients or treatments. The biomarkers may not reliably predict toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients on treatment for cancer at UHCW NHS Trust

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (Age \>18 years) * Histologically/Cytological confirmed solid tumour * Treated with radical RT or concurrent chemo-RT (Cohort 1) OR * Treated with chemo-IO or IO-IO combination (Cohort 2) * First-line treatment * Able to provide informed consent * Willing to comply with study procedures Exclusion Criteria: * Contraindication for RT or chemotherapy (Cohort 1) OR * Contraindication for chemotherapy or IO (Cohort 2) * Use of chemotherapy or immunotherapy in the last 5 years. (Cohort 1) OR * Use of radical RT or chemo-RT within the thorax in the last 5 years. (Cohort 2) * Beyond first-line treatment (second line onwards) * Has more than 1 active cancer requiring treatment * Recent participation in an interventional study * Pregnant or breastfeeding women * On long term cytotoxics or immune-modulators for rheumatoid arthritis or connective tissue disorders or auto-immune disorders * Poor life expectancy, likely less than 6 months * Patients not likely to comply with treatment or the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biomarker discovery and validation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biomarker discovery and validation Cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospitals Coventry & Warwickshire NHS Trust

    RECRUITING

    Coventry, CV2 2DX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.